Key Highlights

• Net profit after tax was $186.9 million, down 5.9%, as FY25 Investment returns and tax benefits normalised.

• Policyholder growth slowed to 1.9% and sales exceeded 147,000, up 4.3%.

• International UOP rose 15.1% to $35.1 million, with policyholder growth of 4.4% and a net Margin of about 15%.

• FY27 group UOP guidance of $265 million to $285 million is subject to RE outcomes.

Why would a health insurer guide to higher Underlying Profit when its largest segment saw Earnings fall? nib Holdings (ASX:NHF) did exactly that on 24 August 2026. For FY26, group underlying operating profit (UOP) rose 9.1% to $260.9 million, even though Australian residents Health Insurance (ARHI) UOP fell 9.6% to $187.9 million. Growth in international, New Zealand and related businesses made up the difference, and management guided FY27 group UOP to $265 million to $285 million, excluding nib Travel.

The central development: Diversification offsets pressure at home

Group Revenue rose 6.2% to $3.8 billion. Net profit after tax was $186.9 million, down 5.9%, as FY25 investment returns and tax benefits normalised. The Operating Expense ratio improved 110 basis points to 16.6%. Operating Cash Flow rose 20.2% to $199 million, and net tangible assets rose almost 15% to $341 million. Gearing fell to 15% and EBITDA Leverage was 0.6 times.

The final Dividend was 21.0 cents per share, including a 5 cent special dividend. The target ordinary Payout Ratio is now 65% to 75%. Special dividends are not repeatable by definition, so investors should look at the ordinary component when assessing ongoing income.

Australian residents health insurance

ARHI revenue rose 6.4% to just over $3 billion. Policyholder growth slowed to 1.9% and sales exceeded 147,000, up 4.3%. The net margin was 6.2%, with an underlying margin of 6.3%, and claims Inflation moderated to 4.1%, or 4.5% including NSW bed rate changes. The non-marketing expense ratio fell to 5.3%.

The earnings fall was mainly due to risk equalisation (RE) and rebate impacts. RE is the industry mechanism that shares high claims costs across insurers, and nib's RE costs rose about 10%, roughly $10 million above expectations. Industry gross Deficit inflation rose to about 7.5% from about 5%, and the usual gap between nib and the industry has narrowed.

A regulatory clarification means Acquisition offers can no longer attract the Australian Government rebate, and management said the average cost of an acquisition offer rose about 25% as a result.

International, New Zealand and related businesses

International UOP rose 15.1% to $35.1 million, with policyholder growth of 4.4% and a net margin of about 15%. New Zealand UOP was $27.5 million, versus a $2.9 million loss in FY25, helped by premium increases and co-payment changes; policyholders fell 8.3%, which management said was ahead of expectations. Health services UOP was $2.4 million after a $5.9 million loss. nib Thrive, the NDIS-related business, delivered $16.3 million, $0.6 million lower, with participant growth uncertain until NDIS reforms are clearer. Related businesses overall delivered $86.1 million of UOP, about one-third of group earnings.

nib concluded a strategic review of nib Travel; sale proceeds of about $97 million in net cash are expected in the first half of FY27, with Allianz Partners becoming a long-term distribution partner. Completion is pending.

Outlook

FY27 group UOP guidance of $265 million to $285 million is subject to RE outcomes. In ARHI, management expects broadly stable gross margin, subject to RE, and an underlying net margin within its 6% to 7% target range. It also expects further productivity gains, a lower operating expense ratio and significantly lower one-off costs. Digital and AI productivity delivered $61 million in FY26, or $79 million cumulatively since FY24.

Sector and competitive position

Larger insurers hold most of the market, and nib competes through price, digital distribution and add-on services. Its international and New Zealand businesses diversify, but they carry their own regulatory and claims risks.

Material risks

- Risk equalisation Volatility could reduce margin again.

- Churn and competitor promotions affecting policyholder growth.

- Claims development adjustments, which affected first-half (6.8%) and second-half (5.5%) margins.

- Capital headroom: the PCA ratio was 1.65 times against a 1.5 to 1.6 times target, but management noted less headroom after the health fund dividend.

- NDIS reform affecting nib Thrive.

- Completion risk for the nib Travel sale.

Reading the margin guidance

The ARHI net margin of 6.2% sits within the 6% to 7% target range, but the half-year pattern was uneven, with reported margins of 6.8% in the first half and 5.5% in the second. That volatility reflects claims-liability adjustments and risk equalisation outcomes rather than a clear trend. For FY27, management's guidance of a margin within the target range, with significantly lower one-off costs, implies stability rather than expansion in the core margin, which is a reasonable base case but not a certainty.

Capital and dividends

Gearing of 15% and EBITDA leverage of 0.6 times indicate a conservative non-regulated balance sheet, and the expected $97 million of nib Travel proceeds will add to it. Within the regulated health funds, however, the PCA ratio of 1.65 times leaves less headroom than before after the health fund dividend. Because a Special Dividend of 5 cents was included in the final, the ordinary final dividend is effectively 16 cents.

What to monitor next

Investors may follow the first-half FY27 result in early 2027, settlement of the nib Travel sale, premium determinations and RE announcements, policyholder growth in ARHI, dental product changes effective 1 October, and any government decisions on the private health rebate or acquisition offers.